Loading...
PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib
Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...
Na minha lista:
| Udgivet i: | Cell Death Dis |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833744/ https://ncbi.nlm.nih.gov/pubmed/29472524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0344-0 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|